SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Avalo Therapeutics, Inc. – ‘10-K’ for 12/31/21 – ‘EX-10.5’

On:  Wednesday, 3/2/22, at 4:03pm ET   ·   For:  12/31/21   ·   Accession #:  1628280-22-4671   ·   File #:  1-37590

Previous ‘10-K’:  ‘10-K’ on 3/8/21 for 12/31/20   ·   Next:  ‘10-K’ on 3/29/23 for 12/31/22   ·   Latest:  ‘10-K’ on 3/29/24 for 12/31/23   ·   51 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/02/22  Avalo Therapeutics, Inc.          10-K       12/31/21   91:11M                                    Workiva Inc Wde… FA01/FA

Annual Report   —   Form 10-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.40M 
 2: EX-4.15     Instrument Defining the Rights of Security Holders  HTML     46K 
 3: EX-10.5     Material Contract                                   HTML     34K 
 4: EX-21.1     Subsidiaries List                                   HTML     24K 
 5: EX-23.1     Consent of Expert or Counsel                        HTML     30K 
 6: EX-31.1     Certification -- §302 - SOA'02                      HTML     29K 
 7: EX-31.2     Certification -- §302 - SOA'02                      HTML     29K 
 8: EX-32.1     Certification -- §906 - SOA'02                      HTML     28K 
14: R1          Cover                                               HTML     88K 
15: R2          Audit Information                                   HTML     29K 
16: R3          Consolidated Balance Sheets                         HTML    130K 
17: R4          Consolidated Balance Sheets (Parenthetical)         HTML     42K 
18: R5          Consolidated Statements of Operations and           HTML    127K 
                Comprehensive Loss                                               
19: R6          Consolidated Statements of Changes in               HTML    120K 
                Stockholders' Equity                                             
20: R7          Consolidated Statements of Cash Flows               HTML    141K 
21: R8          Business                                            HTML     33K 
22: R9          Significant Accounting Policies                     HTML     70K 
23: R10         Aytu Divestiture                                    HTML     53K 
24: R11         Revenue                                             HTML     35K 
25: R12         Net Loss Per Share                                  HTML     63K 
26: R13         Asset Acquisition                                   HTML     28K 
27: R14         Fair Value Measurements                             HTML     48K 
28: R15         Property and Equipment                              HTML     63K 
29: R16         Goodwill and Intangible Assets                      HTML     52K 
30: R17         Accrued Expenses and Other Current Liabilities      HTML     38K 
31: R18         Notes Payable                                       HTML     53K 
32: R19         Capital Structure                                   HTML     51K 
33: R20         Stock Based Compensation                            HTML    105K 
34: R21         Income Taxes                                        HTML     77K 
35: R22         Commitments and Contingencies                       HTML     55K 
36: R23         Subsequent Events                                   HTML     27K 
37: R24         Significant Accounting Policies (Policies)          HTML    127K 
38: R25         Aytu Divestiture (Tables)                           HTML     48K 
39: R26         Net Loss Per Share (Tables)                         HTML     61K 
40: R27         Fair Value Measurements (Tables)                    HTML     43K 
41: R28         Property and Equipment (Tables)                     HTML     65K 
42: R29         Goodwill and Intangible Assets (Tables)             HTML     54K 
43: R30         Accrued Expenses and Other Current Liabilities      HTML     38K 
                (Tables)                                                         
44: R31         Notes Payable (Tables)                              HTML     45K 
45: R32         Capital Structure (Tables)                          HTML     35K 
46: R33         Stock Based Compensation (Tables)                   HTML     92K 
47: R34         Income Taxes (Tables)                               HTML     72K 
48: R35         Business (Details)                                  HTML     56K 
49: R36         Significant Accounting Policies (Details)           HTML     41K 
50: R37         Aytu Divestiture - Narrative (Details)              HTML     63K 
51: R38         Aytu Divestiture - Summary of Assets and            HTML     35K 
                Liabilities (Details)                                            
52: R39         Aytu Divestiture - Summary of Income Statement      HTML     45K 
                (Details)                                                        
53: R40         Aytu Divestiture - Summary of Cash Flows (Details)  HTML     30K 
54: R41         Revenue (Details)                                   HTML     74K 
55: R42         Net Loss Per Share - Narrative (Details)            HTML     39K 
56: R43         Net Loss Per Share - Computation of Basic and       HTML     67K 
                Diluted Net Loss Per Share of Common Stock for                   
                Continuing and Discontinued Operations (Details)                 
57: R44         Net Loss Per Share - Anti-dilutive Securities       HTML     45K 
                (Details)                                                        
58: R45         Asset Acquisition (Details)                         HTML     52K 
59: R46         Fair Value Measurements - Assets and Liabilities    HTML     34K 
                from Continuing Operations (Details)                             
60: R47         Fair Value Measurements - Narrative (Details)       HTML     28K 
61: R48         Property and Equipment - Summary of Property and    HTML     39K 
                Equipment (Details)                                              
62: R49         Property and Equipment - Narrative (Details)        HTML     53K 
63: R50         Property and Equipment - Supplemental Balance       HTML     39K 
                Sheet Information (Details)                                      
64: R51         Property and Equipment - Lease Cost (Details)       HTML     26K 
65: R52         Property and Equipment - Lease Maturity (Details)   HTML     43K 
66: R53         Goodwill and Intangible Assets - Narrative          HTML     37K 
                (Details)                                                        
67: R54         Goodwill and Intangible Assets - Schedule of        HTML     31K 
                Intangible Assets Rollforward (Details)                          
68: R55         Goodwill and Intangible Assets - Schedule of        HTML     39K 
                Finite Lived Intangible Assets (Details)                         
69: R56         Accrued Expenses and Other Current Liabilities -    HTML     42K 
                Schedule of Accrued Expenses and Other Current                   
                Liabilities (Details)                                            
70: R57         Notes Payable - Narrative (Details)                 HTML     73K 
71: R58         Notes Payable - Balance Sheet Information           HTML     47K 
                (Details)                                                        
72: R59         Notes Payable - Estimated Future Principal          HTML     48K 
                Payments (Details)                                               
73: R60         Capital Structure - Narrative (Details)             HTML    148K 
74: R61         Capital Structure - Common Stock Warrants           HTML     41K 
                (Details)                                                        
75: R62         Stock Based Compensation - Narrative (Details)      HTML    192K 
76: R63         Stock Based Compensation - Stock-based              HTML     34K 
                Compensation Expense (Details)                                   
77: R64         Stock Based Compensation - Stock Options With       HTML     78K 
                Service-based Vesting Conditions (Details)                       
78: R65         Stock Based Compensation - Stock Options With       HTML     56K 
                Company's Market-based Option Activity (Details)                 
79: R66         Stock Based Compensation - Stock-based              HTML     47K 
                Compensation Assumptions (Details)                               
80: R67         Stock Based Compensation - Restricted Stock Units   HTML     38K 
                (Details)                                                        
81: R68         Income Taxes - Narrative (Details)                  HTML     41K 
82: R69         Income Taxes - Schedule of Income Tax Provision     HTML     46K 
                (Details)                                                        
83: R70         Income Taxes - Schedule of Deferred Taxes           HTML     52K 
                (Details)                                                        
84: R71         Income Taxes - Expense (Details)                    HTML     44K 
85: R72         Commitments and Contingencies (Details)             HTML    168K 
86: R73         Subsequent Events (Details)                         HTML     27K 
89: XML         IDEA XML File -- Filing Summary                      XML    160K 
87: XML         XBRL Instance -- avtx-20211231_htm                   XML   2.10M 
88: EXCEL       IDEA Workbook of Financial Reports                  XLSX    124K 
10: EX-101.CAL  XBRL Calculations -- avtx-20211231_cal               XML    233K 
11: EX-101.DEF  XBRL Definitions -- avtx-20211231_def                XML    987K 
12: EX-101.LAB  XBRL Labels -- avtx-20211231_lab                     XML   2.21M 
13: EX-101.PRE  XBRL Presentations -- avtx-20211231_pre              XML   1.37M 
 9: EX-101.SCH  XBRL Schema -- avtx-20211231                         XSD    228K 
90: JSON        XBRL Instance as JSON Data -- MetaLinks              479±   710K 
91: ZIP         XBRL Zipped Folder -- 0001628280-22-004671-xbrl      Zip    808K 


‘EX-10.5’   —   Material Contract


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 <!   C:   C: 
  Document  

Exhibit 10.5
Avalo Therapeutics, Inc.

Non- Employee Director Compensation Policy

Amended January 24, 2022

Each member of the Board of Directors (the “Board”) who is not also serving as an employee of Avalo Therapeutics, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy for his or her Board service on and following the date this policy is adopted by the Compensation Committee of the Board (the “Effective Date”). An Eligible Director may decline all or any portion of his or her compensation by giving notice to the Company prior to the date cash is to be paid or equity awards are to be granted, as the case may be. This policy is effective as of the Effective Date and may be amended at any time in the sole discretion of the Board or the Compensation Committee of the Board.

Annual Cash Compensation

The annual cash compensation amount set forth below is payable in equal quarterly installments, payable in arrears on the last day of each calendar quarter in which service occurred. If an Eligible Director joins the Board or a committee of the Board at a time other than effective as of the first day of a calendar quarter, each retainer set forth below for such quarter will be pro-rated based on days served in the applicable calendar quarter, with regular full quarterly payments thereafter. Likewise, if an Eligible Director ceases to serve on the Board or a committee of the Board at a time other than effective as of the last day of a calendar quarter, each retainer set forth below for such quarter will be pro-rated based on days served in the applicable calendar quarter. All annual cash fees are vested upon payment.

1.Annual Board Service Retainer:

a.All Eligible Directors: $40,000

b.Chair of the Board Service Retainer (in addition to Eligible Director Service Retainer): $30,000

2.Annual Committee Member Service Retainer:

a.Member of the Audit Committee: $7,500

b.Member of the Compensation Committee: $5,000

c.Member of the Nominating and Corporate Governance Committee: $4,000

d.Member of the Science and Technology Advisory Committee: $7,500




3.Annual Committee Chair Service Retainer (in addition to Committee Member Service Retainer):

a.Chair of the Audit Committee: $7,500

b.Chair of the Compensation Committee: $5,000

c.Chair of the Nominating and Corporate Governance Committee: $4,000

d.Chair of the Science and Technology Advisory Committee: $7,500

Election to Receive Stock Options in Lieu of Cash

An Eligible Director may make an election to receive all or a portion of his or her annual cash compensation described above in the form of stock options to purchase shares of the Company’s common stock (the “Common Stock”). Elections must be made in multiples of 5% of an Eligible Director’s aggregate cash retainer.

1.Timing of Elections:

a.Current Eligible Directors: Elections must be made prior to the beginning of each quarter.

b.New Eligible Directors: Elections for the first quarter of service must be made within 30 days of becoming an Eligible Director, provided that such election shall be applicable only to the portion of the cash retainers earned after the date of the election.

c.New committee member or committee chair: Elections for the first quarter of service must be made prior to the date that the Eligible Director becomes a committee member or committee chair (or, if a new Eligible Director, within 30 days of becoming a committee member or committee chair, provided that such election shall be applicable only to the portion of the cash retainer earned after the date of the election).

2.Description of Stock Options: The stock options will be granted under the Company’s 2016 Omnibus Incentive Compensation Plan, as amended (the “Plan”). The stock options will be granted on the date on which the cash would otherwise have been paid (i.e. on the last day of each calendar quarter). All stock options granted will be nonqualified stock options using the Company’s standard form of Nonqualified Stock Option Grant Agreement under the Plan, with an exercise price per share equal to the last reported sale price of the Common Stock on the NASDAQ Capital Market on the date of grant or, if such grant date is not a trading date, on the last trading date prior to the grant date, and with a term of ten years from the date of grant (subject to earlier termination in connection with a termination of service as provided in the Plan). The actual number of shares subject to the stock options will be determined so that the options have a “fair value” on the date of grant, using a Black-Scholes or binominal valuation model consistent with the methodology used by the Company in preparing its financial
-2-


statements, equal to the amount of cash fees forgone. The stock options will immediately vest and become exercisable in full upon grant.

Equity Compensation

The equity compensation set forth below will be granted under the Plan. All stock options granted under this policy will be nonqualified stock options using the Company’s standard form of Nonqualified Stock Option Grant Agreement under the Plan, with an exercise price per share equal to the last reported sale price of the Common Stock on the NASDAQ Capital Market on the date of grant or, if such grant date is not a trading date, on the last trading date prior to the grant date, and with a term of ten years from the date of grant (subject to earlier termination in connection with a termination of service as provided in the Plan).

1.Initial Grant for New Eligible Directors: For each Eligible Director who is first appointed or elected to the Board following the Effective Date, on the date of such election or appointment (or, if such date is not a market trading day, the first market trading day thereafter), such Eligible Director will be automatically, and without further action by the Board or the Compensation Committee of the Board, be granted a stock option for 80,000 shares of Common Stock. The stock options will vest and become exercisable in three substantially equal annual installments on the first, second and third anniversary of the date of grant, subject to the Eligible Director’s continued service on each such vesting date.

2.Annual Grant: On the date of each annual stockholders meeting of the Company held after the Effective Date, each Eligible Director who continues to serve as a non-employee member of the Board following such stockholders meeting will be automatically, and without further action by the Board or the Compensation Committee of the Board, be granted a stock option for 40,000 shares of Common Stock. The stock options will vest and become exercisable in full on the first anniversary of the grant date, subject to the Eligible Director’s continued service on such vesting date.
-3-

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:3/2/228-K
1/24/22
For Period end:12/31/214
 List all Filings 


7 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/29/24  Avalo Therapeutics, Inc.          10-K       12/31/23   83:9.6M                                   Workiva Inc Wde… FA01/FA
 5/04/23  Avalo Therapeutics, Inc.          S-8         5/04/23    4:91K                                    Workiva Inc Wde… FA01/FA
 3/29/23  Avalo Therapeutics, Inc.          10-K       12/31/22   82:10M                                    Workiva Inc Wde… FA01/FA
 2/03/23  Avalo Therapeutics, Inc.          424B5                  1:1.1M                                   Workiva Inc Wde… FA01/FA
 2/02/23  Avalo Therapeutics, Inc.          424B5                  1:1.1M                                   Workiva Inc Wde… FA01/FA
 1/13/23  GoHealth, Inc.                    S-8         1/13/23    4:872K
11/07/22  Avalo Therapeutics, Inc.          S-8        11/07/22    4:108K                                   Workiva Inc Wde… FA01/FA


44 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/09/21  Avalo Therapeutics, Inc.          10-Q        9/30/21   75:8.7M                                   Workiva Inc Wde… FA01/FA
 8/26/21  Avalo Therapeutics, Inc.          8-K:5,8,9   8/26/21   13:387K                                   Workiva Inc Wde… FA01/FA
 8/02/21  Avalo Therapeutics, Inc.          10-Q        6/30/21   76:10M                                    Workiva Inc Wde… FA01/FA
 6/08/21  Avalo Therapeutics, Inc.          8-K:1,2,9   6/04/21   19:1.1M                                   Workiva Inc Wde… FA01/FA
 5/13/21  Avalo Therapeutics, Inc.          10-Q        3/31/21   70:7.9M                                   Workiva Inc Wde… FA01/FA
 3/08/21  Avalo Therapeutics, Inc.          10-K       12/31/20   82:11M                                    Workiva Inc Wde… FA01/FA
 3/01/21  Avalo Therapeutics, Inc.          8-K:5,8,9   3/01/21   15:376K                                   Workiva Inc Wde… FA01/FA
 1/08/21  Avalo Therapeutics, Inc.          8-K:1,8,9   1/07/21   18:807K                                   Workiva Inc Wde… FA01/FA
11/20/20  Avalo Therapeutics, Inc.          8-K:1,8,9  11/16/20   14:272K                                   Workiva Inc Wde… FA01/FA
 8/06/20  Avalo Therapeutics, Inc.          10-Q        6/30/20   68:13M                                    Workiva Inc Wde… FA01/FA
 6/18/20  Avalo Therapeutics, Inc.          8-K:5,9     6/18/20    2:247K                                   Workiva Inc Wde… FA01/FA
 5/07/20  Avalo Therapeutics, Inc.          10-Q        3/31/20   65:7.5M                                   Workiva Inc Wde… FA01/FA
 4/27/20  Avalo Therapeutics, Inc.          8-K:5,9     4/21/20    5:304K                                   Workiva Inc Wde… FA01/FA
 3/18/20  Avalo Therapeutics, Inc.          8-K:1,3,9   3/17/20    3:306K                                   Workiva Inc Wde… FA01/FA
 3/11/20  Avalo Therapeutics, Inc.          10-K       12/31/19   95:13M                                    Workiva Inc Wde… FA01/FA
 2/04/20  Avalo Therapeutics, Inc.          8-K:1,9     2/03/20    3:191K                                   Toppan Merrill/FA
 2/03/20  Avalo Therapeutics, Inc.          8-K:1,2,5,9 1/31/20   10:1.7M                                   Workiva Inc Wde… FA01/FA
12/11/19  Avalo Therapeutics, Inc.          8-K/A:1,3,712/05/19    2:516K                                   Workiva Inc Wde… FA01/FA
11/14/19  Aevi Genomic Medicine, LLC        10-Q        9/30/19   43:3.3M                                   Toppan Merrill/FA
11/04/19  Avalo Therapeutics, Inc.          8-K:1,2,7,911/01/19    5:285K                                   Workiva Inc Wde… FA01/FA
10/15/19  Avalo Therapeutics, Inc.          8-K:1,7,9  10/10/19    3:1M                                     Workiva Inc Wde… FA01/FA
 9/09/19  Avalo Therapeutics, Inc.          8-K:1,3,9   9/04/19    3:299K                                   Workiva Inc Wde… FA01/FA
 8/13/19  Aevi Genomic Medicine, LLC        10-Q        6/30/19   44:3.7M                                   Toppan Merrill/FA
 5/14/19  Aevi Genomic Medicine, LLC        10-Q        3/31/19   43:4.3M                                   Toppan Merrill/FA
12/27/18  Avalo Therapeutics, Inc.          8-K:1,3,5,912/26/18    6:544K                                   Toppan Merrill/FA
 9/18/18  Avalo Therapeutics, Inc.          8-K:1,2,9   9/14/18    2:506K                                   Toppan Merrill/FA
 8/20/18  Avalo Therapeutics, Inc.          8-K:1,3,9   8/17/18    3:295K                                   Toppan Merrill/FA
 8/02/18  Aevi Genomic Medicine, LLC        10-Q        6/30/18   37:4.5M                                   Toppan Merrill/FA
 5/17/18  Avalo Therapeutics, Inc.          8-K:3,5,9   5/15/18    4:457K                                   Toppan Merrill/FA
 5/11/18  Avalo Therapeutics, Inc.          10-Q        3/31/18   65:7.3M                                   Workiva Inc Wde… FA01/FA
 4/27/18  Avalo Therapeutics, Inc.          8-K:5,9     4/23/18    3:145K                                   Toppan Merrill/FA
 5/10/17  Aevi Genomic Medicine, LLC        10-Q        3/31/17   35:2.1M                                   Toppan Merrill/FA
 4/28/17  Avalo Therapeutics, Inc.          8-K:1,3,5,8 4/27/17    6:964K                                   Toppan Merrill/FA
11/08/16  Avalo Therapeutics, Inc.          10-Q        9/30/16   51:5.3M                                   Toppan Merrill Bridge/FA
 8/04/16  Aevi Genomic Medicine, LLC        10-Q        6/30/16   37:4M                                     Toppan Merrill/FA
 5/20/16  Avalo Therapeutics, Inc.          S-8         5/20/16    4:726K                                   Toppan Merrill Bridge/FA
 5/20/16  Avalo Therapeutics, Inc.          8-K:5,9     5/18/16    3:543K                                   Toppan Merrill Bridge/FA
 3/23/16  Avalo Therapeutics, Inc.          10-K       12/31/15   66:9.1M                                   Toppan Merrill Bridge/FA
12/22/15  Aevi Genomic Medicine, LLC        8-K:1,7,9  12/18/15    3:53K                                    Toppan Merrill/FA
10/22/15  Aevi Genomic Medicine, LLC        10-Q        9/30/15   43:5M                                     Toppan Merrill/FA
10/13/15  Avalo Therapeutics, Inc.          S-1/A      10/09/15    8:3.8M                                   Toppan Merrill-FA
 9/08/15  Avalo Therapeutics, Inc.          S-1/A       9/04/15   11:3.8M                                   Toppan Merrill-FA
 6/12/15  Avalo Therapeutics, Inc.          S-1                   24:7M                                     Toppan Merrill-FA
 2/13/15  Aevi Genomic Medicine, LLC        10-K       12/31/14   68:9.2M                                   Toppan Merrill/FA
Top
Filing Submission 0001628280-22-004671   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Wed., May 15, 4:08:11.3pm ET